Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells 11,767 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 11,767 shares of the business’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $36.01, for a total transaction of $423,729.67. Following the sale, the insider directly owned 2,231 shares of the company’s stock, valued at $80,338.31. This represents a 84.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

William Guyer also recently made the following trade(s):

• On Wednesday, March 4th, William Guyer sold 8,233 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.99, for a total transaction of $296,305.67.
• On Tuesday, February 3rd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $40.87, for a total transaction of $817,400.00.
• On Tuesday, January 6th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $35.18, for a total transaction of $703,600.00.

Corcept Therapeutics Price Performance

Corcept Therapeutics stock opened at $33.82 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85. The stock has a market cap of $3.60 billion, a price-to-earnings ratio of 41.24 and a beta of 0.29. The firm has a 50-day moving average of $37.34 and a two-hundred day moving average of $61.30. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The company had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. During the same period last year, the business posted $0.26 earnings per share. The business’s revenue was up 11.1% compared to the same quarter last year. On average, research analysts forecast that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Institutional Trading of Corcept Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp grew its stake in Corcept Therapeutics by 0.5% during the 4th quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock worth $103,915,000 after buying an additional 15,656 shares during the last quarter. Geode Capital Management LLC raised its stake in Corcept Therapeutics by 38.0% in the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock valued at $92,892,000 after buying an additional 734,646 shares during the last quarter. Morgan Stanley raised its stake in Corcept Therapeutics by 34.1% in the fourth quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock valued at $55,404,000 after buying an additional 405,081 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Corcept Therapeutics by 546.9% in the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock worth $125,264,000 after acquiring an additional 1,274,215 shares in the last quarter. Finally, TD Asset Management Inc grew its stake in shares of Corcept Therapeutics by 4.0% during the fourth quarter. TD Asset Management Inc now owns 994,844 shares of the biotechnology company’s stock worth $34,621,000 after acquiring an additional 38,708 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on CORT shares. HC Wainwright decreased their target price on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Zacks Research downgraded Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research note on Wednesday, December 31st. UBS Group assumed coverage on Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $77.17.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Recent media coverage highlighted Corcept among Q4 earnings outperformers, which can support investor optimism about near‑term revenue momentum and lift sentiment. Q4 earnings outperformers: Corcept (NASDAQ:CORT) and the rest of the branded pharmaceuticals stocks
• Neutral Sentiment: Multiple short‑interest reports claim a “large increase” but show 0 shares / NaN and a 0.0 days‑to‑cover metric — the figures are contradictory and suggest a data/reporting error rather than a genuine surge in shorting. Investors should monitor for corrected filings (FINRA/NYSE data) before drawing conclusions.
• Negative Sentiment: A wave of securities‑class action filings and law‑firm solicitations has emerged following an FDA rejection and a federal court patent loss cited in notices — Hagens Berman and other firms say the suit alleges management concealed regulatory warnings and pipeline readiness issues. Litigation risk raises potential for legal costs, settlements, and management distraction, which can pressure the stock. CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
• Negative Sentiment: Multiple plaintiff firms (Kirby McInerney, Pomerantz, Bronstein Gewirtz, Levi & Korsinsky, Wolf Haldenstein, Rosen, Schall, Portnoy, etc.) have issued notices and are soliciting lead plaintiff motions, with an April 21, 2026 lead‑plaintiff deadline. The coordinated legal activity amplifies the reputational and financial risk. CORT DEADLINE NOTICE: Corcept Therapeutics Incorporated Investors Encouraged to Contact Kirby McInerney LLP By April 21, 2026

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.